MXPA05012768A - Dispositivo polimerico implantable para liberacion prolongada de nalmefeno. - Google Patents

Dispositivo polimerico implantable para liberacion prolongada de nalmefeno.

Info

Publication number
MXPA05012768A
MXPA05012768A MXPA05012768A MXPA05012768A MXPA05012768A MX PA05012768 A MXPA05012768 A MX PA05012768A MX PA05012768 A MXPA05012768 A MX PA05012768A MX PA05012768 A MXPA05012768 A MX PA05012768A MX PA05012768 A MXPA05012768 A MX PA05012768A
Authority
MX
Mexico
Prior art keywords
nalmefene
treatment
sustained release
polymeric device
implantable polymeric
Prior art date
Application number
MXPA05012768A
Other languages
English (en)
Inventor
Louis R Bucalo
Original Assignee
Titan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Titan Pharmaceuticals Inc filed Critical Titan Pharmaceuticals Inc
Publication of MXPA05012768A publication Critical patent/MXPA05012768A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invencion proporciona composiciones, metodos y kits para la administracion de nalmefeno para el tratamiento del alcoholismo, dependencia a la nicotina, u otra condicion para la cual el tratamiento con nalmefeno es terapeuticamente beneficioso. La invencion proporciona un dispositivo polimerico no degradable biocompatible que libera nalmefeno continuamente con cinetica de liberacion generalmente lineal por periodos de tiempo prolongados. El nalmefeno se libera a traves de los poros que se abren a la superficie de la matriz polimerica en la cual se encapsula. El dispositivo se puede administrar subcutaneamente a un individuo en necesidad del tratamiento continuo con nalmefeno.
MXPA05012768A 2003-05-30 2004-05-27 Dispositivo polimerico implantable para liberacion prolongada de nalmefeno. MXPA05012768A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47491603P 2003-05-30 2003-05-30
PCT/US2004/016944 WO2004110400A2 (en) 2003-05-30 2004-05-27 Implantable polymeric device for sustained release of nalmefene

Publications (1)

Publication Number Publication Date
MXPA05012768A true MXPA05012768A (es) 2006-02-22

Family

ID=33551514

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012768A MXPA05012768A (es) 2003-05-30 2004-05-27 Dispositivo polimerico implantable para liberacion prolongada de nalmefeno.

Country Status (8)

Country Link
US (1) US20050031668A1 (es)
EP (1) EP1638536A2 (es)
JP (1) JP2007502866A (es)
AU (1) AU2004247057A1 (es)
CA (1) CA2526101A1 (es)
MX (1) MXPA05012768A (es)
WO (1) WO2004110400A2 (es)
ZA (1) ZA200509063B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
ZA200507877B (en) 2003-03-31 2007-01-31 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
PT1781264E (pt) 2004-08-04 2013-10-16 Evonik Corp Métodos para o fabrico de dispositivis de administração e dispositivos para a mesma
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
JP5502751B2 (ja) 2007-12-20 2014-05-28 エボニック コーポレイション 低残留溶媒濃度を有する微粒子を調製するためのプロセス
RU2545865C2 (ru) * 2009-09-22 2015-04-10 Евоник Корпорейшн Имплантируемые устройства с различными вариантами загрузки биологически активного компонента
LT2547332T (lt) 2010-03-16 2018-12-10 Titan Pharmaceuticals, Inc. Heterogeninės implantuojamos priemonės, skirtos vaisto pristatymui
AU2017263253B2 (en) * 2016-05-12 2022-04-14 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents
MX2019003804A (es) * 2016-10-05 2019-08-05 Titan Pharmaceuticals Inc Dispositivos implantables para suministro de medicamento con liberacion de descarga reducida.
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
EP3801462A4 (en) 2018-05-24 2022-03-16 Celanese EVA Performance Polymers LLC IMPLANTABLE DEVICE FOR EXTENDED RELEASE OF A MACROMOLECULAR DRUG COMPOUND
CN109200017B (zh) * 2018-11-22 2021-03-02 辽宁海思科制药有限公司 一种盐酸纳美芬注射液药物组合物及其制备方法
CN114206336A (zh) * 2019-08-13 2022-03-18 默沙东公司 用于递送抗病毒剂的药物递送系统
BR102020025389A2 (pt) * 2020-12-11 2022-06-21 Edson Luiz Peracchi Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da dependência a nicotina e processo
CA3215040A1 (en) * 2021-04-20 2022-10-27 Oakwood Laboratories, Llc Microsphere formulations comprising nalmefene and methods for making and using the same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069307A (en) * 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4148871A (en) * 1977-10-11 1979-04-10 Pitt Colin G Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers
US4898733A (en) * 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US4692451A (en) * 1985-12-11 1987-09-08 Trustees Of Tufts College Method for preventing stereotypic behavior in animals
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5601835A (en) * 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
DE3879031T2 (de) * 1987-08-08 1993-06-24 Akzo Nv Kontrazeptives implantat.
US5156844A (en) * 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
WO1990015637A2 (en) * 1989-06-21 1990-12-27 Brown University Research Foundation Neurological therapy system
US5219858A (en) * 1990-03-27 1993-06-15 Parnell Pharmaceuticals, Inc. Method and compositions for effecting withdrawal from drug dependency
US5114718A (en) * 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
US5086085A (en) * 1991-04-11 1992-02-04 The United States Of America As Represented By The Department Of Energy Melamine-formaldehyde aerogels
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
FR2695826B1 (fr) * 1992-09-21 1995-01-06 Theramex Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention.
JP3720386B2 (ja) * 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
US5633000A (en) * 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
DE69603577T2 (de) * 1995-02-10 1999-11-25 Medtronic Inc Verfahren und vorrichtung zur verabreichung von analgetika
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US6004962A (en) * 1995-09-11 1999-12-21 Gooberman; Lance L. Rapid opioid detoxification
US5733565A (en) * 1996-02-23 1998-03-31 The Population Council, Center For Biomedical Research Male contraceptive implant
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6271240B1 (en) * 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
US20010036469A1 (en) * 1997-01-13 2001-11-01 Gooberman Lance L. Opiate antagonist implant and process for preparation therefor
US6203813B1 (en) * 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
TW460599B (en) * 1998-01-14 2001-10-21 Toshiba Corp Method for forming fine wiring pattern
AU2981099A (en) * 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
CN1434704A (zh) * 1999-12-16 2003-08-06 三叉技术有限责任公司 延长其受体负荷剂量的治疗剂释放的系统和方法
BR0209198A (pt) * 2001-04-26 2004-06-08 Control Delivery Sys Inc Métodos de sìntese de compostos contendo fenol
US20020198574A1 (en) * 2001-06-22 2002-12-26 Ron Gumpert Automatic sobriety training and reconditioning system
JP2005513050A (ja) * 2001-12-10 2005-05-12 コントロール・デリバリー・システムズ・インコーポレイテッド 尿生殖路疾患の治療
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
ZA200507877B (en) * 2003-03-31 2007-01-31 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
US20050245541A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
WO2007139744A2 (en) * 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst

Also Published As

Publication number Publication date
WO2004110400A2 (en) 2004-12-23
JP2007502866A (ja) 2007-02-15
EP1638536A2 (en) 2006-03-29
CA2526101A1 (en) 2004-12-23
AU2004247057A1 (en) 2004-12-23
US20050031668A1 (en) 2005-02-10
WO2004110400A3 (en) 2005-02-17
ZA200509063B (en) 2007-03-28

Similar Documents

Publication Publication Date Title
HK1177895A1 (en) Implantable polymeric device for sustained release of dopamine agonist
MXPA05012768A (es) Dispositivo polimerico implantable para liberacion prolongada de nalmefeno.
CY1120510T1 (el) Εμφυτευσιμο πολυμερες προϊον για την παρατεταμενη απελευθερωση βουπρενορφινης
WO2007139744A3 (en) Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
IN2014DN10834A (es)
WO2007038246A3 (en) Solid polymer delivery compositions and methods for use thereof
MX2007008923A (es) Microserpentin implantable con superficie de porosidad microscopica.
HUS1600049I1 (hu) Bruton tirozinkináz inhibitorok
EP2407203A3 (en) Solid therapeutic agent for use in an implantable drug delivery device
WO2005115493A3 (en) Thermal treatment of an implantable medical device
MX2007006214A (es) Un implante para suministro de farmaco intraocular.
MXPA05013003A (es) Composiciones de deposito elastomerico implantables, usos de las mismas y metodo para elaboracion.
WO2019071243A8 (en) Implantable depots for the controlled release of therapeutic agents
TW200635616A (en) Organic compounds
WO2008108987A3 (en) Medical device with a porous surface for delivery of a therapeutic agent
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
GB2431346B (en) A combination composition comprising paracetamol and ibuprofen
TW200515919A (en) Bioerodible sustained release drug delivery systems
WO2006130455A3 (en) Bioresorbable polymer matrices and methods of making and using the same
MX362908B (es) Implantes que contienen fármacos y métodos de uso de los mismos.
WO2007123993A3 (en) Niosome-hydrogel drug delivery
WO2006068713A3 (en) 3,3'-diindolylmethane immune activating compositions
ATE480267T1 (de) Zein-beschichtete medizinische vorrichtung
NZ584766A (en) Method, composition, and article of manufacture for providing alpha-1 antitrypsin
MXPA04000418A (es) Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal